Views: 952

Reply to This

Replies to This Discussion

"Our preference is a strategic partner who can share our vision and move at the pace we can move," says Blaustein.

"Blaustein wants to get the mid-stage trial designed and underway in the second half of this year."

Awesome.  

Anybody know the story on this?  Does Charley's Fund have an equity stake in Halo - they own the IP on HT-10 - or what?


I sure hope the bought the IP rights, otherwise what did they buy?

This is the Seckler and Wicka family initiative.

http://online.wsj.com/article/SB10001424052970203686204577115051703...

-David

 

 

Yes, they own it.

So, Halo is the only drug we can hope.Because it is the only project which is time specific!!

“We want to quickly determine if this is a good drug for Duchenne muscular dystrophy,” Mr. Blaustein says. 

Mr. Blaustein estimates that the Seckler and Wicka families will need to raise at least another $8 million to see the drug through a Phase II clinical trial, which aims to find out whether a compound works in patients. He says Halo’s plans for a trial received support from an advisory committee at Treat-NMD, a European Union-funded network of experts who give advice on how to drive drug development for promising neuromuscular medications. The committee wrote in its report this month that it considers the proposed trial “ready for the clinic and extraordinarily well-prepared.”


Is PPMD going to support them?

It will be interesting to say the least to see what PPMD does. It seems to me that the "activist" nature of what Halo is doing may rub more traditional organizations like PPMD or MDA the wrong way. Pat Furlong is quoted in one of the articles with a cautionary tone to be sure.

If you are interested in more, check this out. Its a more in-depth interview of Dr. Seckler than most infotainment news shows.  You have to scroll past the first interview ...

http://www.biocenturytv.com/player/1490703721001

-David

 

I wait with great hope. I want to stay positive, but the statement about starting the trial "in the second half of 2012" is a bit unnerving. Sounds like another typical biotech press release.

I wish I could tell my customers "we'll start sometime between July and December!"

In the last announcement they said that need 8 million and now they have raised 1.1 million will taht be enough to start the phase2 in the second half 2012?

lets keep fingers crossed and keep praying.

This time they  will make this happen. Their commitment is different than those of typical biotech.They are also suffering like us!!

“Our preference is a strategic partner who can share our vision and move at the pace we can move,” says Blaustein."

 So, prayers for Summit and prayers for Halo.

It seems they have raised enough to start phase 2, per this article.

http://www.xconomy.com/boston/2012/05/24/halo-gathers-1-1m-from-pat...

For now, Halo has plenty of resources to take HT-100 into the next stage of testing, thanks to the pooled resources of the patient advocacy groups. Blaustein says he’s not aware of another case of so many nonprofits coming together to fund a single drug, but he won’t be surprised if more such arrangements emerge.

I'm having a terribly hard time finding the scientific literature on the treatment ... I'll share whatever I turn up but there doesn't appear to be much other than these press releases.


Amrit said:

In the last announcement they said that need 8 million and now they have raised 1.1 million will taht be enough to start the phase2 in the second half 2012?

lets keep fingers crossed and keep praying.

David,

 Same here. I am also seeking out for the details on "HT-100 works by inhibiting the pathological fibrotic process in muscle and directly stimulating healthy muscle fiber regeneration"

No clue how is this achieved. Looks like for this time the PR is silent. Hopefully results will do the talking.

 

Boy, even the articles referenced on the Halo web site seem to say very little about how it works. Maybe the mechanism is just beyond laypeople? I dunno.

One abstract did have something interesting, but I sure can't translate it. Maybe somebody else can:

Halofuginone, an inhibitor of the Smad3 phosphorylation, downstream of the TGFβ signaling, inhibits the activation of fibroblasts and their ability to synthesize the extracellular matrix, regardless of their origin or location.

http://informahealthcare.com/doi/abs/10.1517/17460441.3.1.11

Reply to Discussion

RSS

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service